Impact of cytokine gene polymorphism on cardiovascular risk in renal transplant recipients

Cardiovascular events are the leading causes of morbidity and mortality in renal transplant recipients (RTR). Given the role of inflammation in atherosclerosis, the contribution of functional polymorphisms of cytokines to cardiovascular diseases (CVD) was assessed in RTR in this study. Polymorphisms of tumour necrosis factor alpha (TNF‐α) gene [−308 (G→A), −238 (G→A)], interleukin‐10 (IL‐10) gene [−1082(A→G), −819 (T→C), −592 (A→C)], transforming growth factor beta 1 (TGF‐β1) gene [codon 10 (T→C), codon 25 (G→C)], carotis intima media thickness (CIMT), left ventricular mass index (LVMI), 24‐h ambulatory blood pressure and serum lipoprotein homocysteine level, erythrocyte sedimentation rate, serum C‐reactive protein (CRP) and serum fibrinogen level of RTR were determined. Seventy‐two RTR (26 cadaveric allograft, 46 living‐related allograft, 43 male, 29 female) were included in this study. LVMI were similar in TNF‐α, IL‐10 and TGF‐β1 genotypes. Right and left CIMT were higher in TT genotype (n = 16) than CT (n = 46) and CC (n = 10) genotypes of TGF‐β1 codon 10 (T→C) gene polymorphism (RCIMT, 7.7 ± 2.2 mm vs. 7.0 ± 1.4 mm vs. 5.9 ± 1.4 mm, P = 0.025; LCIMT, 8.5 ± 2.5 mm vs. 7.0 ± 1.3 mm vs. 6.1 ± 1.2 mm, P = 0.002). Lipoprotein (a) level of TT genotype (35.5 ± 22.5 mg/dl) was higher than CC (4.1 ± 2.8 mg/dl) and CT (20.4 ± 11.2 mg/dl) genotypes of TGF‐β1 codon 10 (T→C) gene polymorphism (P = 0.037). High producers of cytokine IL‐10 −1082 [GG (n = 22) vs. AA + AG (n = 50)] and low producers of TGF‐β codon 25 [GC + CC (n = 17) vs. GG (n = 55)] had lower IMT of carotid artery but the difference did not reach statistical significance (P > 0.05). The CIMT of renal transplant patients was similar in IL‐10 (−819, −592) and TNF‐α (−308, −238) genotypes. No difference was observed in 24‐h ambulatory blood pressure levels, serum lipoproteins, plasma homocysteine level, erythrocyte sedimentation rate, serum CRP, serum fibrinogen level in IL‐10, TNF‐α and TGF‐β1 genotypes. Besides the well‐known factors, TGF‐β1 gene polymorphisms might play a role in CVD in RTR even at early stages of asymptomatic atherosclerosis.

[1]  J. Bonnet,et al.  The –308 G/A Tumor Necrosis Factor-α Gene Dimorphism: A Risk Factor for Unstable Angina , 2003 .

[2]  U. Binswanger,et al.  TGF-β1 gene expression in stable renal transplant recipients: Influence of TGF-β 1 gene polymorphism and immunosuppression , 2002 .

[3]  T. Georg,et al.  Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. , 2002, Kidney international.

[4]  D. Harlan,et al.  Ethnicity Greatly Influences Cytokine Gene Polymorphism Distribution , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  J. Janowska,et al.  Is there a relationship between left ventricular systolic function and serum cytokines level in patients with coronary artery disease? , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[6]  N. Brooks,et al.  Influence of tumor necrosis factor-alpha gene-308 polymorphism on the development of coronary vasculopathy after cardiac transplantation. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  A. Kastrati,et al.  Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. , 2001, Atherosclerosis.

[8]  M. Pirmohamed,et al.  Polymorphisms in the TNF‐α and TNF‐receptor genes in patients with coronary artery disease , 2001 .

[9]  J. Kaski,et al.  Serum Levels of the Antiinflammatory Cytokine Interleukin-10 Are Decreased in Patients With Unstable Angina , 2001, Circulation.

[10]  M. Perola,et al.  Polymorphisms within the tumor necrosis factor locus and prevalence of coronary artery disease in middle-aged men. , 2001, Atherosclerosis.

[11]  Z. Varghese,et al.  Significance of cytokine gene polymorphism in renal transplantation. , 2001, Transplantation proceedings.

[12]  D. Arveiler,et al.  New polymorphisms in the interleukin‐10 gene – relationships to myocardial infarction , 2001, European journal of clinical investigation.

[13]  J. Chan,et al.  Tumor necrosis factor alpha gene G-308A polymorphism in the metabolic syndrome. , 2000, Metabolism: clinical and experimental.

[14]  M. Yokota,et al.  Association of a T29-->C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. , 2000, Circulation.

[15]  MitsuhiroYokota,et al.  Association of a T29→C Polymorphism of the Transforming Growth Factor-β1 Gene With Genetic Susceptibility to Myocardial Infarction in Japanese , 2000 .

[16]  M. Pfeffer,et al.  Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. , 2000, Circulation.

[17]  Z. Massy,et al.  Carotid atherosclerosis in renal transplant recipients. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  M. Territo,et al.  Interleukin-10 blocks atherosclerotic events in vitro and in vivo. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[19]  R. Terkeltaub.  IL-10: An "immunologic scalpel" for atherosclerosis? , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[20]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[21]  C. Barbagallo,et al.  Carotid atherosclerosis in renal transplant recipients: relationships with cardiovascular risk factors and plasma lipoproteins. , 1999, Transplantation.

[22]  J. Gunn,et al.  Transforming growth factor-beta1 gene polymorphisms and coronary artery disease. , 1998, Clinical science.

[23]  J. Gunn,et al.  Transforming growth factor-beta1 gene polymorphisms and coronary artery disease. , 1998, Clinical science.

[24]  P. Hasleton,et al.  Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. , 1998, Transplantation.

[25]  D. Mann,et al.  Effects of Tumor Necrosis Factor Gene Polymorphisms on Patients With Congestive Heart Failure , 1998 .

[26]  H. Mcdevitt,et al.  Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Takeshita,et al.  Altered plasma levels of cytokines in patients with ischemic heart disease. , 1997, Coronary artery disease.

[28]  M. Lazarus,et al.  An investigation of polymorphism in the interleukin-10 gene promoter. , 1997, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[29]  D. Arveiler,et al.  Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Témoin de l'Infarctus du Myocarde (ECTIM) Study. , 1996, Hypertension.

[30]  A. Kumar,et al.  IL-10 production is enhanced in human T cells by IL-12 and IL-6 and in monocytes by tumor necrosis factor-alpha. , 1996, Journal of immunology.

[31]  P. Weissberg,et al.  Active and acid-activatable TGF-β in human sera, platelets and plasma , 1995 .

[32]  D. Rifkin,et al.  Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration , 1991, The Journal of cell biology.

[33]  N Reichek,et al.  Echocardiographic Determination of Left Ventricular Mass in Man: Anatomic Validation of the Method , 1977, Circulation.

[34]  R. Straub,et al.  Systemic immunosuppression fails to suppress cardiac cytokine induction in pressure overload hypertrophy in rats. , 2002, Immunobiology.

[35]  S. Stefoni,et al.  Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. , 2002, Kidney international.

[36]  R. Wolfe,et al.  Long-term survival in renal transplant recipients with graft function. , 2000, Kidney international.

[37]  A. Jardine,et al.  Early echocardiographic changes and survival following renal transplantation. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[38]  T. Spector,et al.  Genetic control of the circulating concentration of transforming growth factor type beta1. , 1999, Human molecular genetics.

[39]  J. Uliana.  Effects of a polymorphism in the human tumor necrosis factor a promoter on transcriptional activation (geneticsymajor histocompatibility complexycytokineygene regulationyautoimmune diseases) , 1997 .

[40]  A. Grace,et al.  The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis , 1995, Nature Medicine.

[41]  O. Wiklund,et al.  Arterial wall thickness in familial hypercholesterolemia. Ultrasound measurement of intima-media thickness in the common carotid artery. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.